Ensysce Biosciences Inc
ENSC
NASDAQ
Biotechnology
$0.40
USD
+0.05 (+14.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.23M
Volume 18.2M
Revenue
$4.71M
TTM
-24.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-11.79M
TTM
-72.9%
YoY
Operating Cash Flow
$-9.60M
TTM
-65.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 1.3 | 1.4 | 0.5 | 1.9 | 1.0 |
YoY Growth | +331.7% | +654.4% | -85.6% | +44.4% | -27.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 1.3 | 1.4 | 0.5 | 1.9 | 1.0 |
Selling, General & Administrative | 1.4 | 1.2 | 1.3 | 1.1 | 1.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.3 | 3.1 | 4.2 | 4.7 | 4.5 |
Operating Income | -2.0 | -1.8 | -3.7 | -2.8 | -3.6 |
EBITDA | -2.0 | -1.8 | -3.7 | -2.8 | -3.6 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -1.9 | -1.7 | -3.7 | -2.8 | -3.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.9 | -1.7 | -3.7 | -2.8 | -3.6 |
Consolidated Net Income / Loss | -1.9 | -1.7 | -3.7 | -2.8 | -3.6 |
Net Income Attributable to Common Shareholders | -1.9 | -1.7 | -3.7 | -2.8 | -3.6 |
Basic EPS | -$1.39 | -$0.79 | -$1.29 | -$0.74 | -$0.52 |
Diluted EPS | -$1.39 | -$0.79 | -$1.29 | -$0.74 | -$0.52 |
Basic Shares Outstanding | 1.4M | 2.2M | 2.9M | 3.7M | 6.8M |
Diluted Shares Outstanding | 1.4M | 2.2M | 2.9M | 3.7M | 6.8M |